Many studies have been carried out using stem-like population enriched by a stem cell marker CD133, and these have demonstrated an increased resistance of CD133+ stem-like tumor cells to treatment with chemotherapeutic agents compared with CD133- tumor progenies. Here, PROM1 is linked to neoplasm.